Senesco and Mayo Clinic partner on multiple myeloma
BRIDGEWATER, N.J.—Senesco Technologies Inc. recently announced that it has finalized a clinical trial agreement with the Mayo Clinic in Rochester, Minn., to study SNS01-T, the company's lead therapeutic candidate for the treatment of multiple myeloma.
Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B- lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells.
The study is an open-label, multiple-dose, dose-escalation study that will evaluate the safety and tolerability of SNS01-T when administered by intravenous infusion to relapsed or refractory multiple myeloma patients. The study design calls for twice-weekly dosing of patients for six weeks, followed by a safety data review period, before escalating to a higher dose level in a new group of patients. While the primary objective of the initial study is to evaluate safety and tolerability, the effect of SNS01-T on tumor response also will be assessed using multiple well-established metrics including measurement of the monoclonal protein (M-protein).
The study is expected to start in the third quarter.
Senesco was previously granted orphan drug status for SNS01-T, the company's lead drug candidate for treatment of multiple myeloma.
The principal investigator in the study at the Mayo Clinic is Dr. John A. Lust.